StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
8156.HK$0.21-2.75%
Fair $0.21+0.0%

8156.HK

Sinopharm Tech Holdings Limited

Technology / Software - ApplicationHKSE

$0.21

-0.01 (-2.75%)

Fairly Valued+0.0%Fair Value $0.21Fund rank 26/100 · Data gapFallback financials|
SA 35/D
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-12.6M · quality 47.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 11/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

35/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists.
Thesis & Journal · 8156.HKLocal privado en este navegador · Sinopharm Tech Holdings Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$134M

P/E

21.2x

↓

EV/EBITDA

22.0x

↑

ROE

9.9%

↑

Gross Margin

12.2%

↓

Debt/Equity

-0.37

↓
52-Week Range$0
$0$0

TradingView lightweight chart

8156.HK price, volumen y niveles de valoración

Último $0.212Periodo -98.8%
Fair value: $0.212

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

-19.0%

FCF CAGR

—

FCF margin

-30.5%

FCF / Net income

0.64x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $41.3M · net income $-19.7M · FCF $-12.6M

2021-FY → 2024-FY

Gross margin

12.2%-14.7% pts

Operating margin

-28.5%+22.3% pts

Net margin

-47.7%+88.9% pts

FCF margin

-30.5%-9.5% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$41.3M$41.3M$42.8M$41.0M$77.8M
Net Income$-19.7M$-19.7M$-10.6M$-88.0M$-106.3M
EBITDA$5.0M$5.0M$-271000.00$-75.3M$-86.1M
EPS-0.11-0.11-0.06-0.49-0.62
Gross Margin12.2%12.2%12.8%14.5%26.8%
Operating Margin-28.5%-28.5%-36.4%-73.4%-50.8%
Net Margin-47.7%-47.7%-24.8%-214.7%-136.7%
Balance Sheet
Debt/Equity-0.37-0.37-0.31-0.28-0.78
Current Ratio0.660.66———
Cash Flow
Free Cash Flow$-12.6M$-12.6M$4.7M$-36.9M$-16.3M
Returns
ROE9.9%9.9%6.2%52.8%76.6%
Valuation
P/E21.2021.20———
EV/EBITDA22.0022.00———
Growth & Yield
Revenue Growth-3.6%-3.6%4.5%-47.3%—
EPS Growth-78.7%-78.7%87.8%20.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +71.0%

Total return

+71.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.06 → -0.11

Residual

+71.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+71.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.